A private equity group with offices on the US East and West Coasts has over $1 billion in assets under management, and is investing from a third fund of over $500 million. The firm makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. The firm primarily invests in North America and the European Union but may also consider opportunities in the Middle East.
The firm invests in biotechnology, medical technology, diagnostics, healthcare services, and healthcare IT. The firm is generally agnostic regarding indications. The firm invests at a range of stages, from development through to profitability, but prefers to back technologies that have attained proof of concept data.
The firm invests in both pre-revenue companies and post-revenue companies. The firm typically leads or co-leads investments, and prefers to take a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment